Table 4.

Use of intravenous respiratory syncytial virus immunoglobulin

• Consider for prophylaxis in infants < 2 years receiving oxygen therapy for bronchopulmonary dysplasia

• Infants born < 32 weeks with bronchopulmonary dysplasia are likely to benefit from 6–12 months' prophylaxis

• Infants born > 32 weeks with bronchopulmonary dysplasia may not benefit

• Should not be used in cyanotic congenital heart disease

• Not evaluated in paediatric or adult immunocompromised patients

• Main emphasis in nosocomial outbreaks should be infection control; efficacy is improved in such settings

• Initiate treatment before onset of respiratory syncytial virus season

• Defer live virus vaccines (e.g. MMR) until last dose